64.93
-2.59 (-3.84%)
| Previous Close | 67.52 |
| Open | 65.07 |
| Volume | 177,473 |
| Avg. Volume (3M) | 286,940 |
| Market Cap | 1,413,045,632 |
| Price / Earnings (Forward) | 10.88 |
| Price / Sales | 2.13 |
| Price / Book | 3.64 |
| 52 Weeks Range | |
| Earnings Date | 8 May 2025 - 12 May 2025 |
| Profit Margin | -3.02% |
| Operating Margin (TTM) | 0.80% |
| Diluted EPS (TTM) | -1.04 |
| Quarterly Revenue Growth (YOY) | 44.80% |
| Total Debt/Equity (MRQ) | 147.17% |
| Current Ratio (MRQ) | 2.72 |
| Operating Cash Flow (TTM) | 64.02 M |
| Levered Free Cash Flow (TTM) | 28.57 M |
| Return on Assets (TTM) | 0.83% |
| Return on Equity (TTM) | -4.18% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | ANI Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.5 |
| Average | 1.13 |
|
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 11.22% |
| % Held by Institutions | 97.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 94.00 (HC Wainwright & Co., 44.77%) | Buy |
| Median | 85.50 (31.68%) | |
| Low | 80.00 (Jefferies, 23.21%) | Buy |
| Average | 86.25 (32.84%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 63.76 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 11 Apr 2025 | 86.00 (32.45%) | Buy | 64.93 |
| 05 Mar 2025 | 86.00 (32.45%) | Buy | 59.68 | |
| HC Wainwright & Co. | 17 Mar 2025 | 94.00 (44.77%) | Buy | 64.35 |
| 03 Mar 2025 | 94.00 (44.77%) | Buy | 58.46 | |
| Jefferies | 14 Mar 2025 | 80.00 (23.21%) | Buy | 62.49 |
| JP Morgan | 12 Mar 2025 | 85.00 (30.91%) | Buy | 63.26 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |